Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
Go back to Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases| Fabien Corp (NASDAQ: FBIO) | Delayed: 2.55 +0.04 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.51 | 52 Week High | $4.66 | |||
| Open | $2.50 | 52 Week Low | $2.01 | |||
| Day High | $2.55 | P/E | N/A | |||
| Day Low | $2.47 | EPS | $0.00 | |||
| Volume | 80,934 | |||||
| (NASDAQ: MBIO) | Delayed: 0.51 +0.02 (4.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.49 | 52 Week High | $ | |||
| Open | $0.49 | 52 Week Low | $ | |||
| Day High | $0.53 | P/E | N/A | |||
| Day Low | $0.49 | EPS | $ | |||
| Volume | 39,368 | |||||
